DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for Benign Ovarian Neoplasm — screening already-approved drugs against its 8-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleBenign Ovarian Neoplasm maps to a 8-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for benign ovarian neoplasm is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
G protein-coupled receptor 6 (GPR6) — GPR6 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 2rdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8TF5 · 2.1 Å · ligand (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate (OLC). Experimental structure, not a prediction.
What the evidence adds up to
A 14-year-old premenarchal girl presented with chronic abdominal pain, constipation, and abdominal enlargement. A computed tomography scan detected a large left ovarian cystic tumour, and a 9-kg ovarian tumour was removed surgically. Pathology showed a benign mucinous cystadenoma. The authors note that ovarian neoplasms in children present a diagnostic quandary and diagnoses are often missed or delayed; when diagnosis is made, prompt fertility-preserving surgical treatment must be performed and followed to prevent recurrence.
In a separate screening study of genetic alterations in ovarian neoplasms, immunohistochemistry was used to examine BRAF, ROS-1, and HER2 in 13 mucinous carcinomas, 12 clear cell carcinomas, 9 endometrioid carcinomas, 9 serous borderline tumours, and 10 high-grade serous tumours of the fallopian tube. No ROS-1 or HER2 abnormalities were identified. BRAF V600E mutations were found in 2 of 9 (22%) borderline serous tumours. The authors state this finding provides a knowledge base to further study the possibility of targeted therapy using a BRAF inhibitor such as vemurafenib on borderline serous tumour of the ovary.
A review of stromal cell ovarian tumours, which represent 7–8% of all ovarian neoplasias, describes this group as characterised by ambiguous prognosis and high recurrence rate. The authors detail problems in early diagnosis of primary stromal cell tumours and their relapses, and note the lack of a unified approach in therapeutic tactics. They state that further investigations of this group are necessary.
What is still missing is prospective data on drug repurposing for benign ovarian neoplasms specifically; the genetic screening data are limited to small numbers and no targeted therapy has been tested in this setting. No unified treatment protocol exists for stromal cell tumours, and early diagnosis remains difficult. Money for larger, stratified trials and a standardised diagnostic approach are lacking.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
American Journal of Case Reports · 2014 · 18 citations · open access
A 9-kg Ovarian Mucinous Cystadenoma in a 14-Year-Old Premenarchal Girl
AbstractPATIENT: Female, 14. FINAL DIAGNOSIS: Ovarian mucinous cystadenoma. SYMPTOMS: Abdominal enlargement • abdominal pain • constipation. MEDICATION: -. CLINICAL PROCEDURE: -. SPECIALTY: Obstetrics and Gynecology. OBJECTIVE: Rare disease. BACKGROUND: Although ovarian tumors are most commonly observed in adults, they relatively rarely occur in children. The majority of ovarian masses encountered in the premenarchal or childhood stages are non-neoplastic lesions such as benign functional cysts. Epithelial tumors account for 8-10% of all ovarian tumors and are histologically classified as mucinous or serous. The most common benign epithelial ovarian tumor is cystadenoma. CASE REPORT: We report the case of a 14-year-old premenarchal girl with chronic abdominal pain, constipation, and abdominal enlargement. A computed tomography detected a huge left ovarian cystic tumor. A 9-kg ovarian tumor was removed surgically. Pathology showed a benign mucinous cystadenoma (MCA). CONCLUSIONS: Ovarian neoplasms in children present a diagnostic quandary, and very often the diagnoses are missed or delayed. When the diagnosis is made, a prompt and fertility-preserving surgical treatment must be performed and followed to prevent recurrence.
Zenodo (CERN European Organization for Nuclear Research) · 2017 · 1 citations · open access
Screening Genetic Alterations of Biomarkers BRAF, ROS-1, and HER2 by Immunohistochemistry in Ovarian Carcinomas for Targeted Therapy
AbstractOvarian neoplasms are group of aggressive and lethal diseases. Surgical and radiochemical therapies on ovarian neoplasm are conventional approaches but with limited progress in years. Targeted therapy with drugs targeting specific genetic alterations and/or protein molecules have brought new hope fighting against ovarian neoplasms. Targeted therapy on genetic alterations of BRAF, ROS-1 and HER2 have been carried out in melanoma, lung cancer and breast cancer with promising results. However, knowledge of these genetic alterations in ovarian neoplasms is limited and deserves further exploration. In this study, we screened genetic alterations of BRAF, ROS-1 and HER2 by immunohistochemistry (IHC) on a variety of ovarian neoplasm, including 13 mucinous carcinomas, 12 clear cell carcinomas, 9 endometrioid carcinomas, 9 serous borderline tumors and 10 high grade serous tumor of fallopian tube. Although ROS-1 and HER2 abnormalities were not identified, BRAF V600E mutations were identified in 2 of 9 (22%) in borderline serous tumors. This finding has provided a knowledge base to further study the possibility of targeted therapy using BRAF inhibitor, such as vemurafeni, on borderline serous tumor of the ovary.
Voprosy Onkologii · 2021 · 0 citations · open access
Stromal cell ovarian tumors
AbstractThis review represents the latest data about rare type of ovarian neoplasms - stromal cell tumors, which are 7-8% of all ovarian neoplasias. This group of diseases is characterized by an ambiguous prognosis and high recurrence rate. The paper presents a general characteristic of an emergency treatment, describes the most common and rare nosologicalal forms. The recent diagnostic and therapeutic approaches are characterised. The authors have shown in detail the problems in early diagnosis of primary stromal cell ovarian tumors and their relapses, the lack of a unified approach in therapeutic tactics and the nessesity for further investigations of this group of ovarian neoplasms.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
